Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | MIF | P14174 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12316694 | 0.84 | MAPT (0.58) | NPC1RAB9AMAPTALDH1A1MIF | |
| SCHEMBL4369707 | 0.80 | NPC1 (0.59) | NPC1RAB9AMAPTALDH1A1MIF | |
| SCHEMBL5993312 | 0.79 | MAPT (0.67) | NPC1RAB9AMAPTALDH1A1MIF | |
| SCHEMBL4361845 | 0.79 | MAPT (0.57) | NPC1RAB9AMAPTALDH1A1MIF | |
| SCHEMBL14096079 | 0.79 | MAPT (0.78) | NPC1RAB9AMAPTALDH1A1MIF | |
| SCHEMBL14096080 | 0.78 | MAPT (0.76) | NPC1RAB9AMAPTALDH1A1MEN1 | |
| SCHEMBL13956743 | 0.77 | NPC1 (0.71) | NPC1RAB9AMAPTALDH1A1MIF | |
| SCHEMBL13956746 | 0.77 | MAPT (0.74) | NPC1RAB9AMAPTALDH1A1MEN1 | |
| SCHEMBL14096127 | 0.77 | MAPT (0.61) | NPC1RAB9AMAPTALDH1A1MIF | |
| SCHEMBL14096078 | 0.77 | MAPT (0.81) | NPC1RAB9AMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | NPC1 886/4885RAB9A 3144/4885MAPT 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.